Solara Active Pharma Sciences Ltd (SOLARA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1003017, "name": "Solara Active", "stock_name": "Solara Active", "full_name": "Solara Active Pharma Sciences Ltd", "name_url": "stocks-analysis/solara-active", "exchange": 0, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "471.20", "chg": -52.95, "chgp": "-10.1%", "dir": -1, "prev_price": "524.15", "mcapval": "1,897.00 Cr", "mcap": "Small Cap", "scripcode": 541540, "symbol": "SOLARA", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE624Z01016", "curr_date": "Feb 06", "curr_time": "", "bse_nse_vol": "4.3 lacs", "exc_status": "Active", "traded_date": "Feb 06, 2026", "traded_date_str": "2026 02 06", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/solara-active-1003017-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Are Solara Active Pharma Sciences Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-solara-active-pharma-sciences-ltd-latest-results-good-or-bad-3826965", "imagepath": "", "date": "2026-02-07 19:23:28", "description": "Solara Active Pharma Sciences Ltd's latest financial results for Q3 FY26 present a complex picture. The company reported a net profit of -₹17.43 crores, indicating a significant decline compared to previous periods. This marks a substantial drop in profitability, as evidenced by a negative PAT margin of -4.99%, down from a positive margin in the prior quarter. Despite this, the company achieved net sales of ₹349.00 crores, reflecting an 11.31% increase on a quarter-over-quarter basis and a 16.21% increase year-on-year. \n\nHowever, the operating margin, excluding other income, fell to 10.70%, down from 17.87% in the previous quarter, highlighting operational challenges that are impacting profitability despite revenue growth. The gross profit margin also deteriorated sharply to 2.33%, suggesting significant cost pressures or unfavorable market conditions.\n\nThe financial performance indicates that while Solara ..." }, { "title": "Solara Active Pharma Falls 6.67%: Margin Pressures and Volatility Weigh on Shares", "link": "https://www.marketsmojo.com/news/stocks-in-action/solara-active-pharma-falls-667-margin-pressures-and-volatility-weigh-on-shares-3826023", "imagepath": "", "date": "2026-02-07 12:04:04", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>2 Feb:</strong> Stock opens strong at Rs.516.80 (+2.37%) despite Sensex decline</p>\n <p><strong>3 Feb:</strong> Continued gains to Rs.524.00 (+1.39%) alongside Sensex rally</p>\n <p><strong>4 Feb:</strong> Peak weekly price at Rs.536.70 (+2.42%) amid moderate volume</p>\n <p><strong>5 Feb:</strong> Sharp reversal to Rs.524.15 (-2.34%) as selling pressure emerges</p>\n <p><strong>6 Feb:</strong> Intraday low and heavy losses at Rs.471.20 (-10.10%) following weak Q3 results</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week..." }, { "title": "Why is Solara Active Pharma Sciences Ltd falling/rising?", "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-solara-active-pharma-sciences-ltd-fallingrising-3825453", "imagepath": "", "date": "2026-02-07 00:46:32", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>Solara Active Pharma’s stock has been on a downward trajectory over the past week, losing 6.67% while the Sensex gained 1.59%. The one-month and year-to-date returns are also deeply negative at -16.70% and -16.36% respectively, significantly underperforming the broader market indices. Over the last year, the stock has declined by 13.86%, contrasting sharply with the Sensex’s 7.07% gain. Even over a three-year horizon, the stock’s 25.69% return lags behind the Sensex’s 38.13%, and the five-year performance is particularly poor with a 65.42% loss compared to the Sensex’s 64.75% gain.</p>\n<p>On 06-Feb, the stock experienced high volatility, trading within a wide intraday range of ₹66.65 and touching a low of ₹462.30, down 11.8% from t..." }, { "title": "Are Solara Active Pharma Sciences Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-solara-active-pharma-sciences-ltd-latest-results-good-or-bad-3824942", "imagepath": "", "date": "2026-02-06 19:29:45", "description": "Solara Active Pharma Sciences Ltd's latest financial results reveal a complex picture of operational performance. In Q2 FY26, the company reported a net profit of ₹10.52 crores, a significant turnaround from a loss of ₹2.10 crores in the previous quarter. This sequential improvement in profitability was accompanied by a quarter-on-quarter revenue increase of 16.90%, reaching ₹319.15 crores. However, year-on-year comparisons indicate a decline in net sales by 12.20% from ₹363.49 crores in Q2 FY25, highlighting ongoing challenges in revenue generation.\n\nThe operating margin for the quarter improved to 17.87%, up from 16.62% in Q1 FY26, suggesting some success in cost management despite remaining below the 19.21% achieved in Q3 FY25. Nevertheless, the return on equity (ROE) remains low at 2.80%, indicating weak capital efficiency and raising concerns about the company's ability to generate adequate returns on ..." }, { "title": "Solara Active Pharma Q3 FY26: Margin Compression Triggers Sharp Loss Despite Revenue Growth", "link": "https://www.marketsmojo.com/news/result-analysis/solara-active-pharma-q3-fy26-margin-compression-triggers-sharp-loss-despite-revenue-growth-3824976", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SolaraActivePha_quaterlyResult_3824976.png", "date": "2026-02-06 17:23:23", "description": "Solara Active Pharma Sciences Ltd., a small-cap pharmaceutical manufacturer specialising in active pharmaceutical ingredients (APIs), reported a disappointing Q3 FY26 performance marked by severe margin compression that overshadowed revenue growth. The company posted a net loss of ₹17.43 crores for the quarter ended December 2025, a sharp deterioration from the ₹10.52 crores profit recorded in Q2 FY26 and significantly worse than the ₹8.09 crores profit in Q3 FY25. The stock plummeted 10.10% to ₹471.20 following the results, reflecting investor concerns about the company's profitability trajectory despite a ₹1,897 crore market capitalisation." }, { "title": "Solara Active Pharma Sciences Ltd Hits Intraday Low Amid Price Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/solara-active-pharma-sciences-ltd-hits-intraday-low-amid-price-pressure-3824544", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SolaraActivePha_priceRelatedfactors_3824544.png", "date": "2026-02-06 15:03:12", "description": "Solara Active Pharma Sciences Ltd experienced a significant intraday decline on 6 Feb 2026, touching a low of Rs 482.2, down 8.06% from the previous close. The stock underperformed its sector and broader market indices, reflecting immediate selling pressure and heightened volatility." }, { "title": "Solara Active Pharma Sciences Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/solara-active-pharma-sciences-ltd-is-rated-strong-sell-3824193", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SolaraActivePha_mojoScore_3824193.png", "date": "2026-02-06 10:10:03", "description": "Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Solara Active Pharma Sciences Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/solara-active-pharma-sciences-ltd-is-rated-strong-sell-3804684", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SolaraActivePha_mojoScore_3804684.png", "date": "2026-01-26 10:10:05", "description": "Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 26 January 2026, providing investors with the latest comprehensive view." }, { "title": "Solara Active Pharma Sciences Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/solara-active-pharma-sciences-ltd-is-rated-strong-sell-3792892", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SolaraActivePha_mojoScore_3792892.png", "date": "2026-01-15 10:10:03", "description": "Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 January 2026, providing investors with the latest insights into the company’s performance and outlook." } ], "total": 616, "sid": "1003017", "stock_news_url": "https://www.marketsmojo.com/news/solara-active-pharma-sciences-1003017" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "07-Feb-2026", "details": "Newspaper Publication on February 07 2026 with respect to the unaudited Financial results for the quarter and nine months ended December 31 2025.", "source": "BSE" }, { "caption": "Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended December 31 2025.", "datetime": "06-Feb-2026", "details": "Solara Active Pharma Sciences Limited has informed the exchange that there is no Deviation and Variation in funds raised through Rights issue for the quarter ended December 31 2025.", "source": "BSE" }, { "caption": "Announcement Under Regulation 30 Of SEBI (LODR) 2015 Regarding The Revision And Adoption Of Policies.", "datetime": "06-Feb-2026", "details": "The Company has reviewed and adopted the revised Policy for Determining Materiality of Events/Information for Disclosure to the Stock Exchanges and Policy for Governance of Related Party Transactions", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Solara Active Pharma Sciences Ltd has declared <strong>30%</strong> dividend, ex-date: 18 Aug 21", "dt": "2021-08-18", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "", "data": [ { "txt": "Solara Active Pharma Sciences Ltd has announced <strong>1:3</strong> rights issue, ex-date: 15 May 24", "dt": "2024-05-15", "middle_text": "Rights Issue" } ] } ] }

Key Events This Week

2 Feb: Stock opens strong at Rs.516.80 (+2.37%) despite Sensex decline

3 Feb: Continued gains to Rs.524.00 (+1.39%) alongside Sensex rally

4 Feb: Peak weekly price at Rs.536.70 (+2.42%) amid moderate volume

5 Feb: Sharp reversal to Rs.524.15 (-2.34%) as selling pressure emerges

6 Feb: Intraday low and heavy losses at Rs.471.20 (-10.10%) following weak Q3 results

Week...

Read full news article

Why is Solara Active Pharma Sciences Ltd falling/rising?

2026-02-07 00:46:32

Recent Price Movement and Market Performance

Solara Active Pharma’s stock has been on a downward trajectory over the past week, losing 6.67% while the Sensex gained 1.59%. The one-month and year-to-date returns are also deeply negative at -16.70% and -16.36% respectively, significantly underperforming the broader market indices. Over the last year, the stock has declined by 13.86%, contrasting sharply with the Sensex’s 7.07% gain. Even over a three-year horizon, the stock’s 25.69% return lags behind the Sensex’s 38.13%, and the five-year performance is particularly poor with a 65.42% loss compared to the Sensex’s 64.75% gain.

On 06-Feb, the stock experienced high volatility, trading within a wide intraday range of ₹66.65 and touching a low of ₹462.30, down 11.8% from t...

Read full news article

Are Solara Active Pharma Sciences Ltd latest results good or bad?

2026-02-06 19:29:45

Solara Active Pharma Sciences Ltd's latest financial results reveal a complex picture of operational performance. In Q2 FY26, the company reported a net profit of ₹10.52 crores, a significant turnaround from a loss of ₹2.10 crores in the previous quarter. This sequential improvement in profitability was accompanied by a quarter-on-quarter revenue increase of 16.90%, reaching ₹319.15 crores. However, year-on-year comparisons indicate a decline in net sales by 12.20% from ₹363.49 crores in Q2 FY25, highlighting ongoing challenges in revenue generation. The operating margin for the quarter improved to 17.87%, up from 16.62% in Q1 FY26, suggesting some success in cost management despite remaining below the 19.21% achieved in Q3 FY25. Nevertheless, the return on equity (ROE) remains low at 2.80%, indicating weak capital efficiency and raising concerns about the company's ability to generate adequate returns on ...

Read full news article

Solara Active Pharma Q3 FY26: Margin Compression Triggers Sharp Loss Despite Revenue Growth

2026-02-06 17:23:23

Solara Active Pharma Sciences Ltd., a small-cap pharmaceutical manufacturer specialising in active pharmaceutical ingredients (APIs), reported a disappointing Q3 FY26 performance marked by severe margin compression that overshadowed revenue growth. The company posted a net loss of ₹17.43 crores for the quarter ended December 2025, a sharp deterioration from the ₹10.52 crores profit recorded in Q2 FY26 and significantly worse than the ₹8.09 crores profit in Q3 FY25. The stock plummeted 10.10% to ₹471.20 following the results, reflecting investor concerns about the company's profitability trajectory despite a ₹1,897 crore market capitalisation.

Read full news article

Solara Active Pharma Sciences Ltd Hits Intraday Low Amid Price Pressure

2026-02-06 15:03:12

Solara Active Pharma Sciences Ltd experienced a significant intraday decline on 6 Feb 2026, touching a low of Rs 482.2, down 8.06% from the previous close. The stock underperformed its sector and broader market indices, reflecting immediate selling pressure and heightened volatility.

Read full news article

Solara Active Pharma Sciences Ltd is Rated Strong Sell

2026-02-06 10:10:03

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Solara Active Pharma Sciences Ltd is Rated Strong Sell

2026-01-26 10:10:05

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 26 January 2026, providing investors with the latest comprehensive view.

Read full news article

Solara Active Pharma Sciences Ltd is Rated Strong Sell

2026-01-15 10:10:03

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

View All News